SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CIANCETTA, Antonella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.937
EU - Europa 2.715
AS - Asia 2.197
SA - Sud America 480
AF - Africa 66
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 9.401
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.855
FI - Finlandia 1.910
SG - Singapore 886
CN - Cina 442
BR - Brasile 376
VN - Vietnam 282
IT - Italia 235
HK - Hong Kong 219
DE - Germania 108
FR - Francia 87
GB - Regno Unito 82
RU - Federazione Russa 61
TR - Turchia 61
JP - Giappone 58
IN - India 56
PL - Polonia 56
UA - Ucraina 56
CA - Canada 41
AR - Argentina 39
SE - Svezia 36
MX - Messico 33
BD - Bangladesh 32
ID - Indonesia 28
ZA - Sudafrica 28
NL - Olanda 24
EC - Ecuador 22
IQ - Iraq 22
PH - Filippine 20
CO - Colombia 15
UZ - Uzbekistan 14
PK - Pakistan 13
AT - Austria 11
ES - Italia 11
TN - Tunisia 9
AE - Emirati Arabi Uniti 8
CZ - Repubblica Ceca 8
MY - Malesia 8
LT - Lituania 7
BE - Belgio 6
KE - Kenya 6
PY - Paraguay 6
VE - Venezuela 6
KR - Corea 5
BO - Bolivia 4
CL - Cile 4
DZ - Algeria 4
EG - Egitto 4
JO - Giordania 4
KZ - Kazakistan 4
MA - Marocco 4
SA - Arabia Saudita 4
TW - Taiwan 4
UY - Uruguay 4
AU - Australia 3
AZ - Azerbaigian 3
CI - Costa d'Avorio 3
IL - Israele 3
JM - Giamaica 3
PE - Perù 3
PT - Portogallo 3
RS - Serbia 3
SY - Repubblica araba siriana 3
BY - Bielorussia 2
CR - Costa Rica 2
ET - Etiopia 2
GA - Gabon 2
IE - Irlanda 2
KH - Cambogia 2
KW - Kuwait 2
LB - Libano 2
MN - Mongolia 2
NP - Nepal 2
PA - Panama 2
PS - Palestinian Territory 2
AL - Albania 1
AM - Armenia 1
BG - Bulgaria 1
CH - Svizzera 1
CV - Capo Verde 1
CY - Cipro 1
EU - Europa 1
GF - Guiana Francese 1
GR - Grecia 1
HU - Ungheria 1
IR - Iran 1
LA - Repubblica Popolare Democratica del Laos 1
MD - Moldavia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
OM - Oman 1
QA - Qatar 1
RO - Romania 1
SN - Senegal 1
TT - Trinidad e Tobago 1
TV - Tuvalu 1
UG - Uganda 1
Totale 9.401
Salva come PNG Salva come JPEG
Città #
Helsinki 1.886
Dallas 1.019
Ashburn 548
Singapore 499
San Jose 320
Hong Kong 212
Santa Clara 209
Beijing 181
Chandler 138
Fairfield 138
Ho Chi Minh City 103
Houston 100
Ferrara 95
Ann Arbor 93
Los Angeles 91
Woodbridge 85
Hanoi 59
Tokyo 57
Jacksonville 55
Warsaw 53
Seattle 52
Wilmington 51
Lauterbourg 46
New York 46
Princeton 46
Cambridge 45
Council Bluffs 38
São Paulo 35
Munich 33
Buffalo 32
Chicago 26
Izmir 25
Orem 24
Shanghai 24
Chennai 21
Jakarta 21
Bologna 19
London 19
San Diego 18
Nuremberg 17
Da Nang 16
Brooklyn 15
Johannesburg 15
Mexico City 15
Milan 15
Stockholm 14
Curitiba 13
Frankfurt am Main 13
Montreal 13
Nanjing 13
Tashkent 13
Turku 13
Atlanta 12
Manchester 12
Washington 12
Baghdad 11
Boardman 11
Denver 11
Redondo Beach 11
Changsha 10
Phoenix 10
Poplar 10
San Francisco 10
Toronto 10
Amsterdam 9
Falls Church 9
Quito 9
Brno 8
Rio de Janeiro 8
The Dalles 8
Boston 7
Brasília 7
Buenos Aires 7
Can Tho 7
Haiphong 7
Hefei 7
Hải Dương 7
Belo Horizonte 6
Brussels 6
Dhaka 6
Lahore 6
Manila 6
Salvador 6
Biên Hòa 5
Calgary 5
Charlotte 5
City of London 5
Guayaquil 5
Osasco 5
Padova 5
Redmond 5
Secaucus 5
Sumaré 5
Venice 5
Amman 4
Aryanah 4
Assago 4
Asunción 4
Cape Town 4
Erbil 4
Totale 7.092
Salva come PNG Salva come JPEG
Nome #
[1,2,4]triazolo[1,5-c]pyrimidines as A(3) adenosine receptor antagonists 2.729
A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy 308
2-Arylpyrazolo[4,3-d]pyrimidin-7-amino derivatives as new potent and selective human A3 adenosine receptor antagonists. Molecular modeling studies and pharmacological evaluation 273
5,7-Disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazines as pharmacological tools to explore the antagonist selectivity profiles toward adenosine receptors 258
Structural refinement of pyrazolo[4,3-d]pyrimidine derivatives to obtain highly potent and selective antagonists for the human A3 adenosine receptor 216
7-Amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives: Structural investigations at the 5-position to target human A(1) and A(2A) adenosine receptors. Molecular modeling and pharmacological studies 189
Novel Aryl Sulfonamide Derivatives as NLRP3 Inflammasome Inhibitors for the Potential Treatment of Cancer 184
Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines and Structurally Simplified Analogs. Chemistry and SAR Profile as Adenosine Receptor Antagonists 183
The influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl moiety on the adenosine receptors affinity profile of pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c] pyrimidine derivatives 180
Design and synthesis of 1,4,8-triazaspiro[4.5]decan-2-one derivatives as novel mitochondrial permeability transition pore inhibitors 162
A 2a adenosine receptor: Structures, modeling, and medicinal chemistry 155
A QM/MM study of the binding of RAPTA ligands to cathepsin B 135
Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report 134
A3 adenosine receptor activation mechanisms: molecular dynamics analysis of inactive, active, and fully active states 133
Bridging molecular docking to membrane molecular dynamics to investigate GPCR-ligand recognition: The human A2A adenosine receptor as a key study 131
Probing non-peptide agonists binding at the human nociceptin/orphanin FQ receptor: a molecular modelling study 128
A Multi-Angle Approach to Predict Peptide-GPCR Complexes: The N/OFQ-NOP System as a Successful AlphaFold Application Case Study 128
null 118
Aquaporin inhibition by gold(III) compounds: New insights 110
DockBench: An Integrated Informatic Platform Bridging the Gap between the Robust Validation of Docking Protocols and Virtual Screening Simulations 107
Revisiting a receptor-based pharmacophore hypothesis for human A(2A) adenosine receptor antagonists 106
Activation of carboplatin by carbonate: A theoretical investigation 106
Deciphering the Complexity of Ligand-Protein Recognition Pathways Using Supervised Molecular Dynamics (SuMD) Simulations 105
Activation of carboplatin by chloride ions: a theoretical investigation 102
Probe Confined Dynamic Mapping for G Protein-Coupled Receptor Allosteric Site Prediction 102
Sensitivity of Binding Free Energy Calculations to Initial Protein Crystal Structure 101
Conjugates between minor groove binders and Zn(II)-tach complexes: Synthesis, characterization, and interaction with plasmid DNA 101
Enhancing Ligand and Protein Sampling Using Sequential Monte Carlo 99
Advances in Computational Techniques to Study GPCR-Ligand Recognition 97
Understanding allosteric interactions in G protein-coupled receptors using Supervised Molecular Dynamics: A prototype study analysing the human A3 adenosine receptor positive allosteric modulator LUF6000 96
Rationalization of the inhibition activity of structurally related organometallic compounds against the drug target cathepsin B by DFT 95
Alternative quality assessment strategy to compare performances of GPCR-ligand docking protocols: the human adenosine A(2A) receptor as a case study 95
Bitopic fluorescent antagonists of the A2A adenosine receptor based on pyrazolo[4,3-: E] [1,2,4]triazolo[1,5- c] pyrimidin-5-amine functionalized congeners 92
New Trends in Inspecting GPCR-ligand Recognition Process: the Contribution of the Molecular Modeling Section (MMS) at the University of Padova 91
null 90
Design and in Vivo Characterization of A 1 Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series 88
Pyrimidine nucleotides containing a (S)-methanocarba ring as P2Y6 receptor agonists 88
Structure-Guided Modification of Heterocyclic Antagonists of the P2Y 14 Receptor 83
Repurposing of a nucleoside scaffold from adenosine receptor agonists to opioid receptor antagonists 82
Advances in GPCR modeling evaluated by the GPCR Dock 2013 assessment: Meeting new challenges 81
Supramolecular delivery systems for polyphenols: A green approach to predict in vivo permeability through an in vitro setup 80
Synthesis and Spectroscopic Characterisation of a Heterodinuclear Iron(III)-Copper(II) Complex Based on an Asymmetric Dinucleating Ligand System 80
Targeting Aquaporin Function: Potent Inhibition of Aquaglyceroporin-3 by a Gold-Based Compound 80
Structure-Based Design of 3-(4-Aryl-1H-1,2,3-Triazol-1-yl)-Biphenyl Derivatives as P2Y14 Receptor Antagonists 78
Demystifying P2Y1 Receptor Ligand Recognition through Docking and Molecular Dynamics Analyses 75
South (S)- and north (N)-methanocarba-7-deazaadenosine analogues as inhibitors of human adenosine kinase 75
Enhancing torsional sampling using fully adaptive simulated tempering 74
Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists 72
Structure activity relationship of 2-arylalkynyl-adenine derivatives as human A3 adenosine receptor antagonists 72
Implementing the “Best Template Searching” tool into Adenosiland platform 71
Perturbation of fluid dynamics properties of water molecules during G protein-coupled receptor-ligand recognition: the human A2A adenosine receptor as a key study 71
Exploring the recognition pathway at the human A2A adenosine receptor of the endogenous agonist adenosine using supervised molecular dynamics simulations 71
Journal of Medicinal Chemistry Collection: Drug Discovery in Italy 70
Purine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A3 Adenosine Receptor Agonists 70
Hidden GPCR structural transitions addressed by multiple walker supervised molecular dynamics (mwSuMD) 69
Breakthrough in GPCR Crystallography and Its Impact on Computer-Aided Drug Design 67
Structural probing and molecular modeling of the A3 adenosine receptor: A focus on agonist binding 63
Influence of key amino acid mutation on the active site structure and on folding in acetyl-CoA synthase: A theoretical perspective 60
Polypharmacology of conformationally locked methanocarba nucleosides 56
In silico 3D modeling of binding activities 54
The path to the G protein-coupled receptor structural landscape: Major milestones and future directions 49
P3.12.20 VAF of EGFR Mutations in Relation to Early Tumor Shrinkage or Deepness of Response During Osimertinib in NSCLC Patients 49
Protein–Ligand Docking: Virtual Screening and Applications to Drug Discovery 47
HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS 47
P2Y14 Receptor 45
Inspecting receptor-ligand interaction using molecular dynamics simulations: new insights from Adenosiland 39
The Effects of Variant Allele Frequency for EGFR Mutation on Early Tumor Shrinkage and Deepness of Response to Osimertinib in Patients with Metastatic Non-Small Cell Lung Cancer: An Exploratory Analysis 11
Totale 9.556
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.077
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.960
Totale 43.037
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202187 0 0 0 0 0 0 0 0 0 45 32 10
2021/2022366 2 16 6 100 16 5 18 61 20 7 13 102
2022/2023313 51 22 24 21 40 26 8 44 47 9 13 8
2023/2024271 16 25 27 12 28 48 14 24 7 4 4 62
2024/20251.244 19 21 98 23 137 100 38 64 229 172 183 160
2025/20266.565 394 383 1.139 452 621 203 508 237 2.212 416 0 0
Totale 9.556